XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasisThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products
| العنوان: | XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasisThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products |
|---|---|
| المؤلفون: | Eric Lamiot, Sylvie Gauthier, Kim Cantin, Réjean DrouinR. Drouin, Yves Pouliot, Christina Juneau, Patrice E. Poubelle |
| المصدر: | Canadian Journal of Physiology and Pharmacology. 85:943-951 |
| بيانات النشر: | Canadian Science Publishing, 2007. |
| سنة النشر: | 2007 |
| مصطلحات موضوعية: | Pharmacology, Autoimmune disease, Whey protein, Physiology, business.industry, General Medicine, medicine.disease, Physiology (medical), Psoriasis, Immunopathology, Immunology, medicine, business, Natural Health Products, Selection (genetic algorithm) |
| الوصف: | Natural health products (NHPs) or complementary and alternative medicine (CAM) are commonly used to prevent disorders or support the usual treatments of many diseases. XP-828L, a whey protein extract, has demonstrated potential benefits for the treatment of mild to moderate psoriasis. The aim of this study was to analyze further clinical data that demonstrated the clinical benefits and safety of the XP-828L in patients with psoriasis and the potential mechanism of action of this product in vitro. Oral administration (2.5 g, twice a day, over 112 days) of XP-828L in 42 human subjects with mild to moderate psoriasis improved their PGA scores (physician’s global assessment). Moreover, no significant changes in haematology or hepatic and renal parameters were observed throughout the study period, indicating the safety of the product. In vitro experiments showed that XP-828L decreased the proliferation of concanavalin A (ConA)-stimulated murine splenocytes and their production of interleukin (IL)-2 and interferon (IFN)-γ. Although the in vivo mechanism of action of XP-828L remains unknown, XP-828L represents an NHP to be used as an alternative or concomitant treatment for mild to moderate psoriasis and potentially for other immune-mediated diseases. |
| تدمد: | 1205-7541 0008-4212 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::7c2dc8d3d5c83455776c05e3ed917e57 https://doi.org/10.1139/y07-084 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........7c2dc8d3d5c83455776c05e3ed917e57 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 12057541 00084212 |
|---|